← Leaderboards
Susan A Gauthier
Weill Medical Coll Of Cornell Univ
$4,743,512
Attributed
$8,475,556
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,475,556 · 5
By mechanism
R01$7,554,304 · 4
U24$921,252 · 1
Top collaborators
- Ajay Gupta5 shared
- Yi Wang5 shared
- Claudia A Chiriboga3 shared
- Karen S Marder3 shared
- Amy Frances Kuceyeski2 shared
- Thanh D Nguyen2 shared
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Ajay Gupta$8,619,189
- Yi Wang$29,689,109
- Claire Henchcliffe$220,220
- Amy Frances Kuceyeski$4,735,170
- Sarah Shizuko Morimoto$4,324,636
Others in their field
Other Emerging Leaders on “Multiple Sclerosis”
- Bjorn E Oskarsson · Mayo Clinic Jacksonville$11,846,278
- Gary Fanger · Rise Therapeutics, Llc$9,656,247
- Hemali Phatnani · New York University School Of Medicine$7,892,246
- David Pitt · Yale University$7,740,406
- Ansuman Satpathy · Stanford University$7,721,054
- Julio Cesar Rojas-Martinez · University Of California, San Francisco$7,570,303
Research focus
Multiple SclerosisDisease ProgressionMultiple Sclerosis PatientInflammationChronicMagnetic Resonance ImagingImageBaseMultiple Sclerosis LesionsMyelinPredispositionAcuteReproducibilityIronBrainLesionMonitorPatient CareMacrophageMagnetismGadoliniumLinkLongitudinal StudiesMicroglia
Grant awards (17)
Multi-Scale, Multi-Modal Imaging Assessment of Trajectories of Cognitive Impairment in Multiple Sclerosis$667,279
R01 · FY2025 · NS · contact PI
Quantification of the Innate Immune Activity within Chronic Lesions as a Novel Treatment Biomarker in Multiple Sclerosis$586,792
R01 · FY2025 · NS · contact PI
Multi-scale, multi-modal imaging assessment of trajectories of cognitive impairment in Multiple Sclerosis$694,369
R01 · FY2024 · NS · contact PI
Quantification of the Innate Immune Activity within Chronic Lesions as a Novel Treatment Biomarker in Multiple Sclerosis$568,701
R01 · FY2024 · NS · contact PI
No-Gd MRI for Monitoring Disease Status in Multiple Sclerosis$635,380
R01 · FY2022 · NS
Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24)$301,140
U24 · FY2022 · NS
Identifying mechanisms of tissue injury in MS lesions: a multi-modality imaging approach$1
R01 · FY2022 · NS · contact PI
No-Gd MRI for Monitoring Disease Status in Multiple Sclerosis$572,878
R01 · FY2021 · NS
Identifying mechanisms of tissue injury in MS lesions: a multi-modality imaging approach$420,110
R01 · FY2021 · NS · contact PI
Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24)$306,816
U24 · FY2021 · NS
Identifying mechanisms of tissue injury in MS lesions: a multi-modality imaging approach$660,812
R01 · FY2020 · NS · contact PI
No-Gd MRI for Monitoring Disease Status in Multiple Sclerosis$512,585
R01 · FY2020 · NS
Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24)$313,296
U24 · FY2020 · NS
Identifying mechanisms of tissue injury in MS lesions: a multi-modality imaging approach$667,748
R01 · FY2019 · NS · contact PI
No-Gd MRI for Monitoring Disease Status in Multiple Sclerosis$537,648
R01 · FY2019 · NS
No-Gd MRI for Monitoring Disease Status in Multiple Sclerosis$530,468
R01 · FY2018 · NS
Identifying mechanisms of tissue injury in MS lesions: a multi-modality imaging approach$499,533
R01 · FY2018 · NS · contact PI